iris prosthesis News
-
CUSTOMFLEX® ARTIFICIALIRIS receives Transitional Pass‐through Payment Status
VEO Ophthalmics, LLC, today announced that the CUSTOMFLEX® ARTIFICIALIRIS has been approved by the Center for Medicare and Medicaid Services (CMS) for transitional pass‐through payment status, effective January 1, 2020. The HCPCS code for the CUSTOMFLEX® ARTIFICIALIRIS that is associated with pass‐through payment is: C1839 Iris prosthesis. The approval by CMS for transitional ...
-
VEO Ophthalmics Launches CUSTOMFLEX ARTIFICIALIRIS in the U.S.
VEO Ophthalmics, LLC, today announced the launch of the CUSTOMFLEX ® ARTIFICIALIRIS, the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from congenital aniridia, acquired defects or other conditions associated with a completely or partially ...
-
VEO Ophthalmics Collaborates with The Masket Foundation for Rare Disease Day
VEO Ophthalmics, LLC announced today that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the U.S. distributor for the CUSTOMFLEX® ARTIFICIALIRIS, a custom-made artificial ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you